Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M B Jacobsen

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Lancet (London, England)|September 6, 2000
Relation between food provocation and systemic immune activation in patients with food intoleranceM B Jacobsen, P Aukrust, E Kittang, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 1999
Expression of p68 protein kinase and its prognostic significance during IFN-alpha therapy in patients with carcinoid tumoursY Zhou, A Gobl, S Wang, et al.
Lancet (London, England)|February 11, 1995
Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costsA Gardulf, V Andersen, J Björkander, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptomsA N Wymenga, B Eriksson, P I Salmela, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Lancet (London, England)|September 6, 2000
Relation between food provocation and systemic immune activation in patients with food intoleranceM B Jacobsen, P Aukrust, E Kittang, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 1999
Expression of p68 protein kinase and its prognostic significance during IFN-alpha therapy in patients with carcinoid tumoursY Zhou, A Gobl, S Wang, et al.
Lancet (London, England)|February 11, 1995
Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costsA Gardulf, V Andersen, J Björkander, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptomsA N Wymenga, B Eriksson, P I Salmela, et al.
Pageof 4